top of page

World's First AI-Solution for Primary Diagnosis of Breast Cancer

  • World's First AI-Solution for Primary Diagnosis of Breast Cancer Deployed by Ibex Medical Analytics and KSM, the Research and Innovation Center of Maccabi Healthcare Services

  • Ibex's Galen™ Breast is rolled out as a first read application, helping pathologists improve accuracy, reduce turnaround time, and streamline reporting

Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-based cancer diagnostics, and KSM, the Research and Innovation Center of Maccabi Healthcare Services – Israel's leading HMO - announced today a first-of-a-kind pilot of Ibex's Galen Breast solution for AI-powered primary diagnosis of breast cancer at Maccabi's Pathology Institute.


Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. Early and accurate detection is critical for effective treatment and saving women's lives.


The pilot at Maccabi's Pathology Institute includes 2,000 breast biopsies on which pathologists will use Galen Breast as a First Read application. It is the first-ever deployment of an AI application for primary diagnosis of breast cancer.


During the pilot, all breast biopsies examined at Maccabi will be digitized using a digital pathology scanner, and automatically analyzed by the Galen Breast solution prior to review by a pathologist. The solution detects suspicious findings on biopsies, such as regions with high probability of including cancer cells, and classifies them to one of three risk levels, ranging from high risk of cancer to benign. The Galen Breast First Read is designed to help pathologists diagnose breast biopsies more accurately, more efficiently, and at a considerably faster turnaround time compared to diagnosis on a microscope.


Ibex's AI solution has been used at Maccabi's Pathology Institute since 2018, and already today, all breast and prostate biopsies undergo AI-based second read, supporting improved accuracy and quality control. The solution alerts when discrepancies between the pathologist's diagnosis and the AI algorithm's findings are detected, thus providing a safety net in case of error or misdiagnosis.


"We are proud to use AI as an integral part of breast cancer diagnosis," said Judith Sandbank, MD and Director of the Pathology Institute at Maccabi. "We have already had a successful experience with Ibex's AI solution, enabling us to implement quality control and perform second read on biopsies, and now we are making a significant leap forward with the integration of AI into primary cancer diagnosis."


"Artificial intelligence is revolutionizing healthcare, and its integration into clinical practice will significantly improve the ability to diagnose cancer quickly and efficiently," said Dr. Chaim Linhart, Co-founder and CTO of Ibex. "Our solutions are used in routine practice in pathology laboratories worldwide, and have already helped detect breast and prostate cancers that were misdiagnosed by pathologists as benign. It is now time to take AI to the next level and employ its capabilities across a broader range of the diagnostic workflow."



 

About Ibex Medical Analytics


Ibex uses AI to develop clinical-grade solutions that help pathologists detect and grade cancer in biopsies. The Galen™ Prostate and Galen Breast are the first-ever AI-powered cancer diagnostics solutions in routine clinical use in pathology and deployed worldwide, empowering pathologists to improve diagnostic accuracy, integrate comprehensive quality control and enable more efficient workflows. Ibex's solutions are built on deep learning algorithms trained by a team of pathologists, data scientists and software engineers.


About KSM


KSM (Kahn-Sagol-Maccabi), the Maccabi Research and Innovation Center, was founded in 2016 in cooperation with Morris Kahn and Sami Sagol. KSM has unique access to Maccabi's professional abilities and wealth of medical knowledge, including a large database of 2.5 million members with 30 years of data collection. We are a strong force in multiple global health areas. Our Innovation & Big Data utilizes advanced data sources and AI technologies. We have founded Israel's largest Biobank (over 450K samples collected and analyzed), Clinical Research activities, and a highly awarded Epidemiological Research department. KSM is leading advanced global health improvements by partnering with well-known scientists, researchers, academic institutions, pharmaceutical companies, startups, and tech companies to create and expedite medical breakthroughs. Our co-operations within the global health eco-system allow us to deliver groundbreaking discoveries and solutions - shaping the future of health.


 

SOURCE: Ibex Medical Analytics


Comentarios


connexion_panel_edited.jpg
CXO_8-in-1.png
subscribe_button.png

 

Disclaimer:

The information contained in this site is for reference only. While we have made every attempt to ensure that the information contained in this site has been obtained from reliable sources, we are not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in this site is provided "as is", with no guarantee of completeness, accuracy, timeliness or of the results obtained from the use of this information, and without warranty of any kind, express or implied, including, but not limited to warranties of performance, merchantability and fitness for a particular purpose. In no event will Ho Hon Asia Limited, its related partnerships or corporations, or the partners, agents or employees thereof be liable to you or anyone else for any decision made or action taken in reliance on the information in this site or for any consequential, special or similar damages, even if advised of the possibility of such damages.
Certain links in this site connect to other websites maintained by third parties over whom we have no control. We make no representations as to the accuracy or any other aspect of information contained in other websites.

2025 @ Inno-Thought and its affiliates. All rights reserved.

bottom of page